
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this supplemental circular or as to the action to be taken, you should consult your licensed securities dealers or other registered institution in securities, bank manager, solicitor, professional accountant or other professional advisers.

If you have sold or transferred all your shares in Shanghai Haohai Biological Technology Co., Ltd.*, you should at once hand this supplemental circular with the enclosed forms of proxy to the purchaser(s) or transferee(s) or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser(s) or transferee(s).

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this supplemental circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this supplemental circular.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6826)

SUPPLEMENTAL CIRCULAR

- (1) ELECTION OF NON-INDEPENDENT NON-EXECUTIVE DIRECTORS OF THE FIFTH SESSION OF THE BOARD**
 - (2) ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF THE FIFTH SESSION OF THE BOARD**
 - (3) ELECTION OF NON-STAFF REPRESENTATIVE SUPERVISORS OF THE FIFTH SESSION OF THE SUPERVISORY COMMITTEE**
- AND**
- SUPPLEMENTAL NOTICE OF AGM**

This supplemental circular should be read together with the circular of the AGM dated 20 May 2022 (the “**First Circular**”). Unless the context otherwise requires, capitalized terms used in this supplemental circular shall have the same meanings as those defined in the First Circular.

The AGM and the H Shareholders’ Class Meeting will be held at 24/F, WenGuang Plaza, No. 1386 Hongqiao Road, Changning District, Shanghai, the PRC on Wednesday, 29 June 2022, respectively, as originally planned, notices of which are set out in the First Circular. A supplemental notice of the AGM notifying the AGM to be held as originally scheduled and containing additional proposed resolutions is set out on pages 21 to 23 of this supplemental circular.

A revised form of proxy for AGM (the “**Revised Form of Proxy**”) is enclosed herewith and shall supersede the form of proxy which was enclosed with the notice and the circular of the Company dated 20 May 2022 in relation to the AGM (the “**Original Form of Proxy**”) and has been despatched to the Shareholders. Shareholders who have duly completed and returned the Original Form of Proxy shall note that the Original Form of Proxy is no longer applicable to the AGM.

If you intend to appoint a proxy to attend the AGM, you are required to complete and return the Revised Form of Proxy in accordance with the instructions printed thereon. The Revised Form of Proxy should be returned by the H Shareholders to the Company’s H share registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not less than 24 hours before the time appointed for holding the AGM or any adjourned meeting thereof (as the case may be), i.e. not later than 1:00 p.m. on Tuesday, 28 June 2022. Completion and return of the Revised Form of Proxy will not preclude you from attending and voting in person at the AGM or at any adjourned meeting (as the case may be) should you so wish, but in such event the instrument appointing a proxy shall be deemed to be revoked.

The Revised Form of Proxy is also published on the websites of the Hong Kong Stock Exchange (www.hkexnews.hk) and the Company (www.3healthcare.com).

References to time and dates in this supplemental circular are to Hong Kong time and dates.

* For identification purpose only

14 June 2022

CONTENTS

	<i>Page</i>
DEFINITIONS	1
LETTER FROM THE BOARD	4
APPENDIX I – BIOGRAPHICAL DETAILS OF THE CANDIDATES FOR THE NON-INDEPENDENT NON-EXECUTIVE DIRECTORS	9
APPENDIX II – BIOGRAPHICAL DETAILS OF THE CANDIDATES FOR THE INDEPENDENT NON-EXECUTIVE DIRECTORS	14
APPENDIX III – BIOGRAPHICAL DETAILS OF THE CANDIDATES FOR THE NON-STAFF REPRESENTATIVE SUPERVISORS	19
SUPPLEMENTAL NOTICE OF 2021 ANNUAL GENERAL MEETING	21

DEFINITIONS

In this supplemental circular, unless the context otherwise requires, the following expressions have the following meanings:

“2021 Restricted A Share Incentive Scheme”	the Company’s 2021 restricted A Share incentive scheme approved and adopted by its Shareholders at the 2022 general meeting, the 2022 first A Shareholders’ class meeting and the 2022 first H Shareholders’ class meeting held on 7 March 2022
“A Share(s)”	ordinary shares in the share capital of the Company with a par value of RMB1.00 each and listed on the Sci-Tech Innovation Board of the SSE and traded in RMB
“A Shareholder(s)”	holder(s) of A Shares
“A Shareholders’ Class Meeting”	the 2022 second A Shareholders’ class meeting of the Company to be held at 24/F, WenGuang Plaza, No. 1386 Hongqiao Road, Changning District, Shanghai, the PRC on Wednesday, 29 June 2022 immediately following the conclusion or adjournment of the AGM
“AGM”	the 2021 annual general meeting of the Company to be held at 24/F, WenGuang Plaza, No. 1386 Hongqiao Road, Changning District, Shanghai, the PRC on Wednesday, 29 June 2022 at 1:00 p.m. or any adjournment thereof and the supplemental notice of which is set out on pages 21 to 23 of this supplemental circular
“Articles of Association”	the Articles of Association of the Company, as amended, revised or supplemented from time to time
“Board”	the board of directors of the Company
“Company”	Shanghai Haohai Biological Technology Co., Ltd.* (上海昊海生物科技股份有限公司), a joint stock company incorporated in the PRC with limited liability and its H Shares and A Shares are listed on the Hong Kong Stock Exchange (Stock Code: 6826) and the Sci-Tech Innovation Board of the SSE (Stock Code: 688366), respectively
“Directors”	directors of the Company

DEFINITIONS

“Group”, “our Group”, “we”, “our” or “us”	our Company and its subsidiaries or, where the context so requires, in respect of the period before our Company became the holding company of its present subsidiaries, the businesses operated by such subsidiaries or their predecessors (as the case may be)
“H Share(s)”	the overseas-listed foreign share(s) in the share capital of the Company with a par value of RMB1.00 each, which are listed on the Main Board of the Hong Kong Stock Exchange and traded in HKD
“H Shareholder(s)”	holder(s) of H Shares
“H Shareholders’ Class Meeting”	the 2022 second H Shareholders’ class meeting of the Company to be held at 24/F, WenGuang Plaza, No. 1386 Hongqiao Road, Changning District, Shanghai, the PRC on Wednesday, 29 June 2022 immediately following the conclusion or adjournment of the A Shareholders’ Class Meeting and the notice of which is set out on pages HCM-1 to HCM-3 of the First Circular
“HK\$” or “HKD”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong Listing Rules”	The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended from time to time
“Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Independent Non-executive Director(s)”	the independent non-executive Director(s) of the Company
“Latest Practicable Date”	8 June 2022
“PRC”	the People’s Republic of China which, for the purpose of this supplemental circular only, excludes the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC

DEFINITIONS

“SFO”	Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Share(s)”	A Share(s) and/or H Share(s)
“Shareholder(s)”	A Shareholder(s) and/or H Shareholder(s)
“SSE”	the Shanghai Stock Exchange
“STAR Market Listing Rules”	the Rules Governing the Listing of Securities on the Sci-Tech Innovation Board of the Shanghai Stock Exchange, as amended from time to time
“Supervisor(s)”	the member(s) of the Supervisory Committee
“Supervisory Committee”	the supervisory committee of the Company
“%”	per cent

LETTER FROM THE BOARD



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6826)

Executive Directors:

Dr. Hou Yongtai (Chairman)
Mr. Wu Jianying (General manager)
Ms. Chen Yiyi
Mr. Tang Minjie

Registered office:

No. 5 Dongjing Road
Songjiang Industrial Zone
Shanghai, the PRC

Non-executive Directors:

Ms. You Jie
Mr. Huang Ming

*Headquarters and principal place of
business in the PRC:*

23/F, WenGuang Plaza
No. 1386 Hongqiao Road
Changning District
Shanghai, the PRC

Independent Non-executive Directors:

Ms. Li Yingqi
Mr. Jiang Zhihong
Mr. Su Zhi
Mr. Yang Yushe
Mr. Zhao Lei

Principal place of business in Hong Kong:

Room 1901, 19/F
Lee Garden One
33 Hysan Avenue
Causeway Bay, Hong Kong

14 June 2022

To the Shareholders

Dear Sir/Madam,

SUPPLEMENTAL CIRCULAR

- (1) ELECTION OF NON-INDEPENDENT NON-EXECUTIVE DIRECTORS OF
THE FIFTH SESSION OF THE BOARD
- (2) ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF
THE FIFTH SESSION OF THE BOARD
- (3) ELECTION OF NON-STAFF REPRESENTATIVE SUPERVISORS OF
THE FIFTH SESSION OF THE SUPERVISORY COMMITTEE
- AND
- SUPPLEMENTAL NOTICE OF AGM

* For identification purpose only

LETTER FROM THE BOARD

I. INTRODUCTION

The purpose of this supplemental circular is to give you the supplemental notice of AGM and to provide you with information regarding the proposed additional ordinary resolutions relating to (1) election of non-Independent Non-executive Directors of the fifth session of the Board, (2) election of Independent Non-executive Directors of the fifth session of the Board, and (3) election of non- staff representative Supervisors of the fifth session of the Supervisory Committee. Cumulative voting systems are adopted in such resolutions. This supplemental circular should be read together with the First Circular.

II. ELECTION OF DIRECTORS OF THE FIFTH SESSION OF THE BOARD

As the fourth session of the Board was established on 27 June 2019 and the term will expire soon, the fifth session of the Board shall therefore be elected and formed according to the Articles of Association and the relevant regulatory requirements. The fifth session of the Board will consist of eleven Directors, comprising four executive Directors, two non-executive Directors and five Independent Non-executive Directors.

A meeting of the Board was convened on 8 June 2022, at which, the Board considered and approved the proposal on the Nomination of the Candidates for the Non-Independent Non-Executive Directors of the Fifth Session of the Board (Additional Resolution 1), and proposed to re-elect Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi, Mr. Tang Minjie, Ms. You Jie and Mr. Huang Ming as the non-Independent Non-executive Directors (including executive Directors and non-executive Directors but excluding Independent Non-executive Directors) of the fifth session of the Board. And the Board considered and approved the proposal on the Nomination of the Candidates for the Independent Non-Executive Directors of the Fifth Session of the Board (Additional Resolution 2), and proposed to nominate Mr. Guo Yongqing and re-elect Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe, Mr. Zhao Lei as Independent Non-executive Directors of the fifth session of the Board.

Six candidates for non-Independent Non-executive Directors shall be submitted to the AGM for voting by cumulative voting process on an item-by-item basis. Five candidates for Independent Non-executive Directors shall be submitted to the AGM for voting by cumulative voting process on an item-by-item basis.

In the event that the above-mentioned candidates for Directors are elected as Directors of the fifth session of the Board, their terms of office will be three years from the date of the approval by the Shareholders at the AGM, while the fourth session of the Board will continue their duties until the fifth session of the Board has been established. The Company will enter into service contracts with the Directors of the fifth session of the Board, the remuneration of whom will be determined in accordance with the Remuneration Plan of the Directors and Supervisors for 2022 approved by the AGM and with reference to their respective duties and responsibilities in the Company and prevailing market conditions, and will be subject to review by the Board and the Remuneration and Appraisal Committee from time to time.

LETTER FROM THE BOARD

Biographical details of each of the candidates for the non-Independent Non-executive Directors proposed to be elected at the AGM are set out in Appendix I to this supplemental circular. Biographical details of each of the candidates for the Independent Non-executive Directors proposed to be elected at the AGM are set out in Appendix II to this supplemental circular.

III. ELECTION OF NON-STAFF REPRESENTATIVE SUPERVISORS OF THE FIFTH SESSION OF THE SUPERVISORY COMMITTEE

As the fourth session of the Supervisory Committee was established on 27 June 2019 and the term will expire soon, the fifth session of the Supervisory Committee shall therefore be elected and formed according to the Articles of Association and the relevant regulatory requirements. The fifth session of the Supervisory Committee will consist of five Supervisors, comprising three non-staff representative Supervisors and two staff representative Supervisors.

A meeting of the Supervisory Committee was convened on 8 June 2022, at which, the Supervisory Committee considered and approved the proposal on the Nomination of the Candidates for the Non-staff Representative Supervisors of the Fifth Session of the Supervisory Committee, and proposed to re-elect Mr. Liu Yuanzhong, Ms. Yang Qing and Mr. Tang Yuejun as the non-staff representative Supervisors of the fifth session of the Supervisory Committee. Three candidates for non-staff representative Supervisors shall be submitted to the AGM for voting by cumulative voting process on an item-by-item basis.

The election of staff representative Supervisors shall be conducted by the staff of the Company democratically. The biographical details of staff representative Supervisors will be disclosed by way of announcement upon conclusion of the democratic election by the staff of the Company.

In the event that the above-mentioned candidates for Supervisors are elected as Supervisors of the fifth session of the Supervisory Committee, their terms of office will be three years. The terms of office of three non-staff representative Supervisors will become effective from the date of approval by the Shareholders at the AGM and the terms of office of two staff representative Supervisor will become effective from the date of democratic election by the staff of the Company, while the fourth session of the Supervisory Committee will continue their duties until the fifth session of the Supervisory Committee has been established. The Company will enter into service contracts with the Supervisors of the fifth session of the Supervisory Committee, the remuneration of whom will be determined in accordance with the Remuneration Plan of the Directors and Supervisors for 2022 approved by the AGM, respectively.

Biographical details of each of the candidates for the non-staff representative Supervisors proposed to be elected at the AGM are set out in Appendix III to this supplemental circular.

LETTER FROM THE BOARD

IV. THE AGM

The AGM will be held at 24/F, WenGuang Plaza, No. 1386 Hongqiao Road, Changning District, Shanghai, the PRC on Wednesday, 29 June 2022 at 1:00 p.m., while the H Shareholders' Class Meeting will be held at 24/F, WenGuang Plaza, No. 1386 Hongqiao Road, Changning District, Shanghai, the PRC, immediately after the conclusion or adjournment of the A Shareholders' Class Meeting (which will be held immediately after the conclusion or adjournment of the AGM). The notices of the AGM and the H Shareholders' Class Meeting are set out on pages AGM-1 to HCM-3 of the First Circular. The supplemental notice of the AGM containing additional proposed resolutions is set out on pages 21 to 23 of this supplemental circular. A revised form of proxy for AGM (the "**Revised Form of Proxy**") is enclosed herewith and shall supersede the form of proxy which was enclosed with the notice and the circular of the Company dated 20 May 2022 in relation to the AGM (the "**Original Form of Proxy**") and has been despatched to the Shareholders. Shareholders who have duly completed and returned the Original Form of Proxy shall note that the Original Form of Proxy is no longer applicable to the AGM.

If you intend to appoint a proxy to attend the AGM, you are required to complete and return the Revised Form of Proxy in accordance with the instructions printed thereon. The Revised Form of Proxy should be returned by the H Shareholders to the Company's H share registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not less than 24 hours before the time appointed for holding the AGM or any adjourned meeting thereof (as the case may be), i.e. not later than 1:00 p.m. on Tuesday, 28 June 2022. Completion and return of the Revised Form of Proxy will not preclude you from attending and voting in person at the AGM or at any adjourned meeting (as the case may be) should you so wish, but in such event the instrument appointing a proxy shall be deemed to be revoked.

The cumulative voting system may be adopted by the Company pursuant to the provisions of the Articles of Association or a resolution of the general meeting for the election of Directors and/or Supervisors at the general meeting. Under the cumulative voting system, where two or more Directors and/or Supervisors are to be elected at the general meeting, the number of votes for each share held by a Shareholder shall be equal to the aggregate number of Directors and/or Supervisors for election under the resolution. The Shareholders may use all of the votes concentrating on one particular person, or may distribute the votes for electing several persons.

V. RESPONSIBILITY STATEMENT

This supplemental circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Hong Kong Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this supplemental circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this supplemental circular misleading.

LETTER FROM THE BOARD

VI. RECOMMENDATION

The Directors (including the Independent Non-executive Directors) considers that all the above resolutions are in the best interests of the Company and the Shareholders as a whole. As such, the Directors recommends the Shareholders to vote in favor of all the resolutions set out in the supplemental notice of the AGM which are to be proposed at the AGM.

The Directors would also like to draw your attention to the additional information set out in the appendices to this supplemental circular.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Hou Yongtai
Chairman

* *For identification purpose only*

Details of the candidates for non-Independent Non-executive Directors proposed to be elected at the AGM are set out below:

EXECUTIVE DIRECTORS

Dr. Hou Yongtai (“**Dr. Hou**”), aged 61, is the chairman and executive Director of the Company. Dr. Hou engaged in postdoctoral research at the pharmacology department of University of Pennsylvania in the U.S. from July 1992 to October 1995. Thereafter, he served as a research investigator at the department of cell and developmental biology of the University of Michigan in the U.S. from 1998 to 2000. From August 2000 to August 2003, he served as a researcher and doctoral degree supervisor at Shanghai Institute of Materia Medica, Chinese Academy of Sciences (中國科學院上海藥物研究所), where he was mainly responsible for establishing screening models for cancer drugs and the application of new biotechnologies on new drugs development. He also served as the overseas manager of the strategy and investment committee at Shanghai Pharmaceutical (Group) Co., Ltd, a company principally engaged in investments, research in pharmaceutical products, medical devices, as well as manufacturing and sale of medical devices from July 2003 to June 2004 and was mainly responsible for assisting its formulation of overseas strategies and implementing its external relations and coordination. During July 2000 to June 2004 and April 2005 to March 2008 at Shanghai Huayuan Life Sciences Research and Development Company Limited (“**Shanghai Huayuan**”) (上海華源生命科學研究開發有限公司), he served various positions such as the deputy general manager and the director of the research and development division. He was mainly responsible for formulating product development strategies, establishing its development team and development base as well as implementing its product research and development plans. He has also served as the chairman of Shanghai Qisheng Biologics Company Limited (“**Shanghai Qisheng**”) (上海其勝生物製劑有限公司), a subsidiary of the Company, from December 2007 to August 2010. He served as the chairman of Haohai Limited, the predecessor of the Company, from September 2009 to the date of conversion of the Company in July 2010. He has been appointed as the chairman and Director of the Company since July 2010, and was redesignated as an executive Director on 7 December 2014. Dr. Hou obtained a master’s degree and a Ph.D. degree from Ohio University in the U.S. in March 1987 and August 1992, respectively.

For the year ended 31 December 2021, the remuneration of Dr. Hou amounted to RMB1,336,000 (including tax). Save as disclosed above, Dr. Hou has not held any directorship in any listed companies in the last three years prior to the Latest Practicable Date, and Dr. Hou does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling Shareholders of the Company. As at the Latest Practicable Date, Dr. Hou holds 5,982,000 A Shares, and was granted 50,000 Restricted Shares pursuant to the 2021 Restricted A Share Incentive Scheme, which have not yet been attributed. Save as disclosed above, there is no other matter or information in relation to the election of Dr. Hou as an executive Director that must be brought to the attention of the Shareholders or disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Hong Kong Listing Rules.

Mr. Wu Jianying (“**Mr. Wu**”), aged 58, is an executive Director and general manager of the Company. Mr. Wu worked as a surgeon at the General Surgery Department of the Second Affiliated Hospital of the Second Military Medical University (第二軍醫大學第二附屬醫院普外科) from 1991 to 1999. He thereafter worked at Shanghai Huayuan from March 2003 to February 2004, at the Shanghai branch of China Huayuan Life Industry Limited (中國華源生命產業有限公司上海分公司) from February 2004 to May 2005 and at Cinkate Pharmaceutical and Chemical Intermediates (Shanghai) Company Limited (欣凱醫藥化工中間體(上海)有限公司), a company principally engaged in development and production of pharmaceutical and chemical intermediates, as well as selling its own products and providing relevant technical advisory services from May 2005 to July 2007. He served as the general manager at Haohai Limited from July 2007 to June 2010. He has been acting as the general manager at Shanghai Qisheng since August 2010, and the general manager and executive director at Shanghai Likangrui Biological Engineering Company Limited (“**Shanghai Likangrui**”) (上海利康瑞生物工程有限公同), a subsidiary of the Company, since December 2010. He served as the director of Haohai Healthcare Holdings Co., Ltd. (“**Haohai Holdings**”), a subsidiary of the Company, since July 2015, the vice chairman of Henan Universe Intraocular Lens Research and Manufacture Company, Ltd (“**Henan Universe**”) (河南宇宙人工晶狀體研製有限公司), a subsidiary of the Company, since August 2015 and then the executive director, the executive director of Shanghai Haohai Medical Technology Development Co., Ltd. (“**Haohai Development**”) (上海昊海醫藥科技發展有限公司), a subsidiary of the Company, since February 2016, the director of Haohai Healthcare Holdings (Cayman) Co., Ltd., a subsidiary of the Company since May 2016, the director of Haohai Healthcare Holdings (BVI) Co., Ltd., a subsidiary of the Company since August 2016, the chairman of Shenzhen New Industries Material of Ophthalmology Co., Ltd. (“**NIMO**”) (深圳市新產業眼科新技術有限公司), a subsidiary of the Company, since November 2016 and the general manager of NIMO since January 2022, the executive director of Eyegood Medical (Zhuhai) Co. Ltd. (“**Zhuhai Eyegood**”) (珠海艾格醫療科技開發有限公司), a former subsidiary of the Company from December 2016 to May 2021, and the director of Contamac Holdings Limited (“**Contamac Holdings**”), a subsidiary of the Company since June 2017, and the director of Haohai Aesthetic Holdings (BVI) Co., Ltd., a subsidiary of our Company since November 2017. He also served as a director of Shanghai Pacific Biological Technology Co., Ltd. (“**Pacific Biological**”) (上海太平洋生物高科技有限公司) and Shanghai Pacific Pharmaceutical Co., Ltd. (“**Pacific Pharmaceutical**”) (上海太平洋藥業有限公司), subsidiaries of the Company since May 2018, and a chairman of Hangzhou Aijinglun Technology Co., Ltd., (“**Hangzhou Aijinglun**”) (杭州愛晶倫科技有限公同), a subsidiary of the Company since April 2020. He also served as the director of International Optical Innovation Holdings Co., Limited, a subsidiary of the Company since November 2020, and the director of Art Vision Technology Co., Limited (“**Art Vision**”), a subsidiary of the Company since January 2021. He also served as the chairman of Shanghai Hengtai Vision Technology Co., Ltd. (“**Hengtai Vision**”) (上海亨泰視覺科技有限公同), a subsidiary of the Company since April 2021, the chairman of Hebei Xinshikang Contact Lens Co., Ltd. (“**Hebei XSK**”) (河北鑫視康隱形眼鏡有限公司), a subsidiary of the Company since April 2021, and the chairman of Xiamen Nanpeng Optical Company Limited (“**Nanpeng Optical**”) (廈門南鵬光學有限公司), a subsidiary of the Company since January 2022. He has been appointed as the Director and general manager of the Company since July 2010, and was redesignated as an executive Director on 7 December 2014. Mr. Wu obtained a master’s degree in clinical medicine from the Second Military Medical University in June 1997 and the practicing doctor qualification in the PRC in May 1999.

For the year ended 31 December 2021, the remuneration of Mr. Wu amounted to RMB1,467,000 (including tax). Save as disclosed above, Mr. Wu has not held any directorship in any listed companies in the last three years prior to the Latest Practicable Date, and Mr. Wu does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling Shareholders of the Company. As at the Latest Practicable Date, Mr. Wu holds 6,000,000 A Shares, and was granted 70,000 Restricted Shares pursuant to the 2021 Restricted A Share Incentive Scheme, which have not yet been attributed. Save as disclosed above, there is no other matter or information in relation to the election of Mr. Wu as an executive Director that must be brought to the attention of the Shareholders or disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Hong Kong Listing Rules.

Ms. Chen Yiyi (“**Ms. Chen**”), aged 40, is an executive Director. Ms. Chen joined the marketing department of Haohai Chemical, a company principally engaged in the production and sale of polyurethane composite duct in July 2006 and worked as the marketing manager and assistant to general manager from January 2007 to December 2009, the supervisor of Henan Universe since November 2016, the director of NIMO since November 2016, the supervisor of Zhuhai Eyegood from December 2016 to May 2021. She has also served as an executive director of Qingdao Huayuan Fine Biological Product Co., Ltd. (青島華元精細生物製品有限公司), a subsidiary of the Company since April 2018, a director of Henan Saimeishi Biotech Co., Ltd (河南賽美視生物科技有限公司), a subsidiary of the Company since February 2019, and a director of Hangzhou Aijinglun since April 2020, and a supervisor of Zhuhai Eyegood Vision Technology Co., Ltd. (艾格視光科技有限公司), a subsidiary of the Company since September 2020. She also served as the director of Art Vision since January 2021, the director of Hengtai Vision since April 2021, the director of Hebei XSK since April 2021, and the director of Nanpeng Optical since January 2022. She has been appointed as the Director since July 2010, and was redesignated as an executive Director on 7 December 2014. Ms. Chen obtained a bachelor of arts in June 2004 and a Master of arts in June 2006 from Huazhong University of Science and Technology.

For the year ended 31 December 2021, the remuneration of Ms. Chen amounted to RMB1,092,000 (including tax). Save as disclosed above, Ms. Chen has not held any directorship in any listed companies in the last three years prior to the Latest Practicable Date, and Ms. Chen does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling Shareholders of the Company. As at the Latest Practicable Date, Ms. Chen holds 400,000 A Shares, was granted 50,000 Restricted Shares pursuant to the 2021 Restricted A Share Incentive Scheme, which have not yet been attributed. Save as disclosed above, there is no other matter or information in relation to the election of Ms. Chen as an executive Director that must be brought to the attention of the Shareholders or disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Hong Kong Listing Rules.

Mr. Tang Minjie (“**Mr. Tang**”), aged 47, is an executive Director, joined the Company in August 2016 as an employee, and became a director of NIMO since November 2016, was appointed as the chief financial officer of the Company on 9 December 2016 and as an executive Director on 14 February 2017, and serves as the director of Contamac Holdings since June 2017, the director of Hengtai Vision since April 2021, and the director of Nanpeng Optical since January 2022. Mr. Tang worked at Ernst & Young during the period from August 1998 to July 2016 and served as an audit partner from July 2010 to July 2016. Mr. Tang obtained a bachelor degree in economics from the former international business school of the University of Shanghai in July 1998, and was qualified as a certified public accountant in the PRC in June 2000 and CPA in the United States in June 2006.

For the year ended 31 December 2021, the remuneration of Mr. Tang amounted to RMB1,222,000 (including tax). Save as disclosed above, Mr. Tang has not held any directorship in any listed companies in the last three years prior to the Latest Practicable Date, and Mr. Tang does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling Shareholders of the Company. As at the Latest Practicable Date, Mr. Tang holds 7,000 H Shares, and was granted 50,000 Restricted Shares pursuant to the 2021 Restricted A Share Incentive Scheme, which have not yet been attributed. Save as disclosed above, there is no other matter or information in relation to the election of Mr. Tang as an executive Director that must be brought to the attention of the Shareholders or disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Hong Kong Listing Rules.

NON-EXECUTIVE DIRECTORS

Ms. You Jie (“**Ms. You**”), aged 60, is a non-executive Director. Ms. You is currently a chief physician at the Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine (上海交通大學醫學院附屬第九人民醫院) and doctoral supervisor at Shanghai Jiaotong University School of Medicine. Ms. You worked as a clinician at the Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine (上海中醫藥大學附屬龍華醫院腫瘤科) from July 2004 to July 2014. She also worked at the Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine from August 2014 until present, and held a position as a director of Shanghai Haolan Corporate Management Co., Ltd (上海昊瀾企業管理有限公司) since January 2018. She has been appointed as a Director since July 2010, and was redesignated as a non-executive Director on 7 December 2014. Ms. You obtained a clinical doctorate degree from Shanghai University of Traditional Chinese Medicine (上海中醫藥大學) in July 2004 and the practicing doctor qualification in the PRC in May 1999. Ms. You is the spouse of Mr. Jiang Wei, a controlling Shareholder of the Company.

For the year ended 31 December 2021, Ms. You did not receive any directors’ remuneration. Save as disclosed above, Ms. You has not held any directorship in any listed companies in the last three years prior to the Latest Practicable Date, and Ms. You does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling Shareholders of the Company. As at the Latest Practicable Date, Ms. You directly

holds 28,800,000 A Shares. She is the spouse of Mr. Jiang Wei and therefore she is deemed under the SFO to be interested in the 50,920,000 A Shares held by Mr. Jiang Wei. Save as disclosed above, there is no other matter or information in relation to the election of Ms. You as a non-executive Director that must be brought to the attention of the Shareholders or disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Hong Kong Listing Rules.

Mr. Huang Ming (“**Mr. Huang**”), aged 47, is a non-executive Director. Mr Huang worked as a manager in Haoyang Investments from September 2008 to June 2010, a director of Haohai Changxing Company Limited, a company principally engaged in the manufacture of plastic products since September 2010 and an executive director of Changxing Haoersi Biotechnology Company Limited (長興昊爾斯生物科技有限公司), a company principally engaged in the research and development of biological and plant products from May 2011 to December 2011. He has been serving as a supervisor of Shanghai Jianhua Fine Biological Products Company Limited (上海建華精細生物製品有限公司), a subsidiary of the Company since November 2007, a supervisor of Shanghai Qisheng since December 2007, and a supervisor of Shanghai Likangrui since December 2010. He also served as the director of Haohai Holdings since July 2015, the supervisor of Haohai Development since February 2016, the director of NIMO since December 2016 the director of Contamac Holdings since June 2017, and the director of China Ocean Group Limited, a subsidiary of the Company since December 2017. He also has served as an associate researcher at Fudan University since October 2017. He also served as a supervisor of Shanghai Qisheng Medical Technology Development Co., Ltd. (上海旗盛醫藥科技發展有限公司), a subsidiary of the Company since April 2018 and served as a supervisor of Pacific Biological and Pacific Pharmaceutical since May 2018. He worked as Secretary of the Board from October 2010 to December 2019, as one of our joint company secretaries from November 2014 to December 2019, respectively. He has been appointed as the Director since July 2010, was re-designated as an executive Director on 7 December 2014, and was re-designated as a non-executive Director on 19 December 2019. He was redesignated as an executive Director on 7 December 2014. Mr. Huang, with former name Huang Ping (黃平), obtained a bachelor of laws in July 1998 and a master of laws in June 2005 from East China University of Political Science and Law (華東政法大學), and a doctoral degree in management from Fudan University in June 2011. He obtained his lawyer qualification in May 1999.

For the year ended 31 December 2021, the remuneration of Mr. Huang amounted to RMB100,000 (including tax). Save as disclosed above, Mr. Huang has not held any directorship in any listed companies in the last three years prior to the Latest Practicable Date, and Mr. Huang does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling Shareholders of the Company. As at the Latest Practicable Date, Mr. Huang holds 2,000,000 A Shares. Save as disclosed above, there is no other matter or information in relation to the election of Mr. Huang as a non-executive Director that must be brought to the attention of the Shareholders or disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Hong Kong Listing Rules.

Details of the candidates for Independent Non-executive Directors proposed to be elected at the AGM are set out below:

Mr. Jiang Zhihong (“**Mr. Jiang**”), aged 54, was elected as an Independent Non-executive Director on 29 June 2020. He is currently the vice president and the chair professor of Macau University of Science and Technology. Mr. Jiang conducted post-doctor research work in the Department of Biochemistry and Molecular Pharmacology of Harvard Medical School in the United States during the period from November 1999 to September 2001. Mr. Jiang has served successively as an assistant professor, associate professor and professor at the School of Chinese Medicine in Hong Kong Baptist University during the period from October 2001 to June 2011. Mr. Jiang graduated from Nagasaki University in Japan with a doctor degree in pharmacy in 1998.

For the year ended 31 December 2021, the remuneration of Mr. Jiang amounted to RMB100,000 (including tax). Save as disclosed above, as at the Latest Practicable Date, Mr. Jiang (i) has not held any other positions with any members of the Group and has not had any other major appointments and professional qualifications; (ii) has not hold any directorships in public companies listed in Hong Kong or any other major exchanges in the last three years; (iii) does not have any relationship with any Directors, senior management, substantial Shareholders or controlling Shareholders of the Company; (iv) does not have any interest in any shares, underlying shares or debentures of the Company and its associated corporations which are required to be disclosed pursuant to Part XV of the SFO. Save as disclosed above, there is no other matter or information in relation to the election of Mr. Jiang as an Independent Non-executive Director that must be brought to the attention of the Shareholders or disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Hong Kong Listing Rules.

Mr. Su Zhi (“**Mr. Su**”), aged 45, was elected as an Independent Non-executive Director on 29 June 2020. He has worked at the Central University of Finance and Economics (“**CUFE**”) (中央財經大學) since June 2009, is currently serving as professor and doctoral supervisor at the CUFE, and the chair professor and the head of the Department of Financial Technology of the School of Finance of CUFE. Mr. Su has been the deputy director of the academic committee of the Institute of International Technology and Economy under the Development Research Center of the State Council (國務院發展研究中心國際技術經濟研究所) since July 2018. Mr. Su has also worked as executive deputy director of CUFE & University of Electronic Science and Technology of China Joint Research Data Center (電子科技大學聯合數據研究中心) since March 2018. He has been an external supervisor of Bank of Guizhou Company Limited (貴州銀行股份有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 6199) since May 2018, an independent director of Changzhou Kaneken Steel Section Co., Ltd. (常州鋼勁型鋼股份有限公司), a company listed on listed on National Equities Exchange and Quotations (stock code: 872632) since September 2020, and an independent director of Fujian Start Group Co., Ltd. (福建實達集團股份有限公司), a company listed on the SSE (stock code: 600734) since November 2021. Mr. Su obtained a doctor’s degree in economics majoring in quantitative economics from Jilin University in June 2006. He engaged in the finance research at the post-doctoral study station of the School of Economics and Management of Tsinghua University from April 2007 to May 2009.

For the year ended 31 December 2021, the remuneration of Mr. Su amounted to RMB100,000 (including tax). Save as disclosed above, as at the Latest Practicable Date, Mr. Su (i) has not held any other positions with any members of the Group and has not had any other major appointments and professional qualifications; (ii) has not hold any directorships in public companies listed in Hong Kong or any other major exchanges in the last three years; (iii) does not have any relationship with any Directors, senior management, substantial Shareholders or controlling Shareholders of the Company; (iv) does not have any interest in any shares, underlying shares or debentures of the Company and its associated corporations which are required to be disclosed pursuant to Part XV of the SFO. Save as disclosed above, there is no other matter or information in relation to the election of Mr. Su as an Independent Non-executive Director that must be brought to the attention of the Shareholders or disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Hong Kong Listing Rules.

Mr. Yang Yushe (“**Mr. Yang**”), aged 59, was elected as an Independent Non-executive Director on 29 June 2020. He has been working at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (“**SIMM**”) (中國科學院上海藥物研究所) since 1998, and is currently the doctoral tutor and second-level researcher of SIMM. His main research areas include original anti-infective drugs, anticoagulant drugs, and central nervous system drug research and development. His representative achievement is the successful development of China’s first new fluoroquinolone drug with independent intellectual property rights – Antofloxacin Hydrochloride in 2009. Mr. Yang won the second prize of the National Technology Invention Award (Rank first) in 2017, the first prize of the Shanghai Technical Invention Award (Rank first) in 2015, the Outstanding Achievement Award of Chinese Pharmaceutical Development for Innovative Medicine Award in 2013, and the title of Shanghai Advanced Worker in 2010 (Model Worker). Mr. Yang obtained a doctor degree in pharmacy from SIMM in 1996.

For the year ended 31 December 2021, the remuneration of Mr. Yang amounted to RMB100,000 (including tax). Save as disclosed above, as at the Latest Practicable Date, Mr. Yang (i) has not held any other positions with any members of the Group and has not had any other major appointments and professional qualifications; (ii) has not hold any directorships in public companies listed in Hong Kong or any other major exchanges in the last three years; (iii) does not have any relationship with any Directors, senior management, substantial Shareholders or controlling Shareholders of the Company; (iv) does not have any interest in any shares, underlying shares or debentures of the Company and its associated corporations which are required to be disclosed pursuant to Part XV of the SFO. Save as disclosed above, there is no other matter or information in relation to the election of Mr. Yang as an Independent Non-executive Director that must be brought to the attention of the Shareholders or disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Hong Kong Listing Rules.

Mr. Zhao Lei (“**Mr. Zhao**”), aged 48, was elected as an Independent Non-executive Director on 29 June 2020. He is currently an associate director and researcher at the Commercial Law Office in the Institute of Law of the Chinese Academy of Social Sciences. Mr. Zhao has served successively as an assistant and adjunct professor in Southwest University of Political Science and Law from 2005 to February 2013, and has served as an associate researcher at the Social Sciences in China Press of the Chinese Academy of Social Sciences from March 2013 to November 2016. Mr. Zhao has worked at the Institute of Law of the Chinese Academy of Social Sciences since December 2016. He has been serving as an independent director of Nanning Department Store Co. Ltd.* (南寧百貨大樓股份有限公司), a company listed on the SSE (stock code: 600712) since April 2018. He has been serving as an independent director of Shenwan Hongyuan Group Co., Ltd., which is listed on both the Shenzhen Stock Exchange (stock code: 000166) and the Hong Kong Stock Exchange (stock code: 6806) since May 2021. Mr. Zhao obtained a doctor degree of Civil and Commercial Law from Southwest University of Political Science and Law in July 2007.

For the year ended 31 December 2021, the remuneration of Mr. Zhao amounted to RMB100,000 (including tax). Save as disclosed above, as at the Latest Practicable Date, Mr. Zhao (i) has not held any other positions with any members of the Group and has not had any other major appointments and professional qualifications; (ii) has not hold any directorships in public companies listed in Hong Kong or any other major exchanges in the last three years; (iii) does not have any relationship with any Directors, senior management, substantial Shareholders or controlling Shareholders of the Company; (iv) does not have any interest in any shares, underlying shares or debentures of the Company and its associated corporations which are required to be disclosed pursuant to Part XV of the SFO. Save as disclosed above, there is no other matter or information in relation to the election of Mr. Zhao as an Independent Non-executive Director that must be brought to the attention of the Shareholders or disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Hong Kong Listing Rules.

Mr. Guo Yongqing (“**Mr. Guo**”), aged 48, has worked at Shanghai National Accounting Institute (上海國家會計學院) since 2002, and is currently a professor at Shanghai National Accounting Institute. Mr. Guo is a non-practicing member of the Chinese Institute of Certified Public Accountants (中國註冊會計師協會) and a member of Accounting Standards for Business Enterprises Consultative Committee of Ministry of Finance (財政部企業會計準則諮詢委員會). Mr. Guo served as an independent director at Chongqing Porton Pharmacy Science & Technology Co., Ltd. (重慶博騰製藥科技股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 300363) during the period from March 2016 to May 2022. Mr. Guo has been serving as an independent non-executive director at Tianjin Capital Environmental Protection Group Company Limited (天津創業環保集團股份有限公司), a company listed on both SSE (stock code: 600874) and the Hong Kong Stock Exchange (stock code: 1065) since December 2015. He has been serving as an independent director at Yango Group Co., Ltd. (陽光城集團股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 000671) since May 2020. He has been serving as an independent director at Shanghai Electric Power Company Limited (上海電力股份有限公司), a company listed on the SSE (stock code: 600021) since June 2021. Mr. Guo has also been serving as a

director at Sanxiang Impression Co., Ltd. (三湘印象股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 000863) since June 2021, and a director at Hwabao Securities Co. Ltd. (華寶證券股份有限公司) since September 2018. Mr. Guo obtained a doctoral degree in management majoring in accounting from Shanghai University of Finance and Economics (上海財經大學) in 2002.

Save as disclosed above, as at the Latest Practicable Date, Mr. Guo (i) has not held any other positions with any members of the Group and has not had any other major appointments and professional qualifications; (ii) has not hold any directorships in public companies listed in Hong Kong or any other major exchanges in the last three years; (iii) does not have any relationship with any Directors, senior management, substantial Shareholders or controlling Shareholders of the Company; (iv) does not have any interest in any shares, underlying shares or debentures of the Company and its associated corporations which are required to be disclosed pursuant to Part XV of the SFO. Save as disclosed above, there is no other matter or information in relation to the election of Mr. Guo as an Independent Non-executive Director that must be brought to the attention of the Shareholders or disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Hong Kong Listing Rules.

Nomination Policy and Procedure for Independent Non-Executive Directors

If the Independent Non-executive Directors will be re-elected at the general meeting, the Nomination Committee should review the overall contribution and service to the Company of the retiring Directors, including their attendance at Board meetings and general meetings (if applicable), and their level of participation and performance on the Board. The Nomination Committee should require the nominee to submit biographical information and the consent to be appointed as a Director; and should review and determine whether retiring Directors still meet the criteria for Director selection. The Nomination Committee should then make recommendations to the Board on the re-election of Directors. If an Independent Non-executive Director is to be re-elected, the recommendations should include the process of identifying the candidate, the reasons for recommending the candidate, the independence of the candidate, the views, perspectives, skills and experience that the candidate can bring to the Board, the candidate's role in promoting the diversity of Board members, etc..

The nomination of new Directors shall be first deliberated by the Nomination Committee of the Board and then submitted to the Board, subject to Shareholders' approval by election at the general meeting. Upon receipt of the proposal on appointment of new Director and the biographical information of the candidate, the Nomination Committee should require the nominee to submit biographical information and the consent to be appointed as a Director, and evaluate the candidate based on the criteria for Director selection to determine whether such candidate is qualified for Directorship. The Nomination Committee should then make recommendations to the Board on the appointment of a suitable candidate to serve as a Director. If an Independent Non-executive Director is proposed to be re-elected, the recommendations should include the process of identifying the candidate, the reasons for recommending the candidate, the independence of the candidate, the views, perspectives, skills and experience that the candidate can bring to the Board, and the candidate's role in promoting the diversity of the members of the Board, etc..

For the purpose of evaluating and determining the candidates of Directors, the Nomination Committee and the Board shall consider the following factors: (i) personal characters; (ii) professional qualifications, skills, knowledge, and experience related to the Group's business and strategy; (iii) willing to devote sufficient time to fulfill the duties of the Directors and members of the special committees of the Board; (iv) whether their appointment is in compliance with the requirements of the Hong Kong Listing Rules and STAR Market Listing Rules regarding the independence of the Board and Directors (including the independence requirements of independent non-executive directors); and (v) whether their appointment is in compliance with the Board diversity policy and any measurable targets adopted by the Nomination Committee to diversify the members of the Board.

The Nomination Committee believes that each of the above-mentioned candidates for Independent Non-executive Directors has the basic knowledge of the operation of a listed company, and respectively has the legal, economic, financial, pharmaceutical or other work experience and professional knowledge as necessary to discharge their duties as Independent Non-executive Directors, will properly discharge their duties and responsibilities as Independent Non-executive Directors, and make positive contribution to the development of the Company. Each of the above-mentioned candidates for Independent Non-executive Directors, will also promote diversity of the Board in a number of aspects, including but not limited to gender, age, educational background, professional experience, expertise and knowledge.

Each of the candidates for Independent Non-executive Directors has confirmed his independence pursuant to Rule 3.13 of the Hong Kong Listing Rules. The Board also considers that each of Mr. Jiang, Mr. Su, Mr. Yang, Mr. Zhao and Mr. Guo meets the independence guidelines set out in Rule 3.13 of the Hong Kong Listing Rules and is independent in accordance with the terms of the guidelines.

Details of the candidates for non-staff representative Supervisors proposed to be elected at the AGM are set out below:

Mr. Liu Yuanzhong (“**Mr. Liu**”), aged 54, is the chairman of the Supervisory Committee and the Shareholder Supervisor. Mr. Liu joined Liming Research Institute of Chemical Industry (黎明化工研究院) in 1992 and served as an engineer from November 1997 to October 2001. He has been working as an engineer and has been responsible for research and development of insulation and car high polymer material at Haohai Chemical since December 2001. He has also been a supervisor of (寧波朗格昊海新材料有限公司) since September 2013. He has been appointed as our Supervisor since July 2010. Mr. Liu obtained a bachelor’s degree in industrial analysis from the Department of Applied Chemistry of Beijing Institute of Chemical Technology (北京化工學院) in July 1992 and a master’s degree in engineering from East China University of Science and Technology (華東理工大學) in June 2009.

For the year ended 31 December 2021, Mr. Liu did not receive any Supervisors’ remuneration. Save as disclosed above, Mr. Liu has not held any directorship in any listed companies in the last three years prior to the Latest Practicable Date. Save as disclosed above, Mr. Liu does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling Shareholders of the Company. As at the Latest Practicable Date, Mr. Liu holds 2,000,000 A Shares. Save as disclosed above, there is no other matter or information in relation to the election of Mr. Liu as a Supervisor that must be brought to the attention of the Shareholders or disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Hong Kong Listing Rules.

Ms. Yang Qing (“**Ms. Yang**”), aged 50, is an independent Supervisor. Ms. Yang engaged in post-doctoral research at the Department of Economics of the University of Vienna in Austria from March 2005 to August 2005 and acted as a visiting scholar at the School of Economics, University of Cambridge in England from September 2006 to September 2007, and participated in the Freeman Fellows Program of the University of Illinois at Urbana-Champaign in the U.S. from August 2011 to May 2012. She has joined Fudan University since July 2001 and has been responsible for research and teaching work, and she is currently a professor in the School of Economics. She has been appointed as the Supervisor since October 2014. Ms. Yang obtained a bachelor’s degree in management information system from Kunming University of Science and Technology (昆明理工大學) in July 1995 and a doctoral degree in management from Fudan University in July 2001.

For the year ended 31 December 2021, the remuneration of Ms. Yang amounted to RMB100,000 (including tax). Save as disclosed above, Ms. Yang has not held any directorship in any listed companies in the last three years prior to the Latest Practicable Date. Save as disclosed above, Ms. Yang does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling Shareholders of the Company. As at the Latest Practicable Date, Ms. Yang does not have any interest in the Shares of the Company within the meaning of Part XV of the SFO. Save as disclosed above, there is no other matter or information in relation to the election of Ms. Yang as a Supervisor that must be brought to the attention of the Shareholders or disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Hong Kong Listing Rules.

Mr. Tang Yuejun (“**Mr. Tang**”), aged 44, is an independent Supervisor. Mr. Tang has worked at the School of Management, Fudan University since July 2006, and has been an associate professor at the School of Management since September 2011. He has also been acting as a master’s degree supervisor of MBA and EMBA since January 2011, a master’s degree supervisor of corporate management since September 2012 until present. He acted as a visiting scholar at the Arizona State University WP Carey School of Business in US from August 2017 to July 2018. He has been appointed as a Supervisor since October 2014. Mr. Tang obtained a bachelor’s degree in economics from Nankai University (南開大學) in June 2001, and a doctoral degree in management from the School of Business of Nankai University in June 2006.

For the year ended 31 December 2021, the remuneration of Mr. Tang amounted to RMB100,000 (including tax). Save as disclosed above, Mr. Tang has not held any directorship in any listed companies in the last three years prior to the Latest Practicable Date. Save as disclosed above, Mr. Tang does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling Shareholders of the Company. As at the Latest Practicable Date, Mr. Tang does not have any interest in the Shares of the Company within the meaning of Part XV of the SFO. Save as disclosed above, there is no other matter or information in relation to the election of Mr. Tang as a Supervisor that must be brought to the attention of the Shareholders or disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Hong Kong Listing Rules.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6826)

SUPPLEMENTAL NOTICE OF 2021 ANNUAL GENERAL MEETING

Reference is made to the notice of the 2021 annual general meeting (the “**AGM**”) of Shanghai Haohai Biological Technology Co., Ltd.* (the “**Company**”) dated 20 May 2022 (the “**First Notice**”), which set out the time and place of the AGM and contained the relevant resolutions to be proposed to the Shareholders at the AGM for their consideration. Unless otherwise indicated, capitalized terms used herein shall have the same meaning as those defined in the circular of the AGM dated 20 May 2022 (the “**First Circular**”) and the supplemental circular of the AGM dated 14 June 2022 (the “**Supplemental Circular**”).

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the AGM will be held as originally scheduled at 1:00 p.m., on Wednesday, 29 June 2022 at 24/F, WenGuang Plaza, No. 1386 Hongqiao Road, Changning District, Shanghai, the PRC, for the purpose of considering the following additional resolutions, together with the other resolutions set out in the First Notice:

Ordinary Resolutions

(Cumulative voting systems are adopted in following resolutions)

1. To consider and approve the resolution on the election of non-Independent Non-Executive Directors of the fifth session of the Board:
 - 1.1 Election of Dr. Hou Yongtai as an executive Director of the fifth session of the Board;
 - 1.2 Election of Mr. Wu Jianying as an executive Director of the fifth session of the Board;
 - 1.3 Election of Ms. Chen Yiyi as an executive Director of the fifth session of the Board;
 - 1.4 Election of Mr. Tang Minjie as an executive Director of the fifth session of the Board;

SUPPLEMENTAL NOTICE OF 2021 ANNUAL GENERAL MEETING

- 1.5 Election of Ms. You Jie as a non-executive Director of the fifth session of the Board; and
- 1.6 Election of Mr. Huang Ming as a non-executive Director of the fifth session of the Board.
2. To consider and approve the resolution on the election of Independent Non-Executive Directors of the fifth session of the Board:
 - 2.1 Election of Mr. Jiang Zhihong as an Independent Non-executive Director of the fifth session of the Board;
 - 2.2 Election of Mr. Su Zhi as an Independent Non-executive Director of the fifth session of the Board;
 - 2.3 Election of Mr. Yang Yushe as an Independent Non-executive Director of the fifth session of the Board;
 - 2.4 Election of Mr. Zhao Lei as an Independent Non-executive Director of the fifth session of the Board; and
 - 2.5 Election of Mr. Guo Yongqing as an Independent Non-executive Director of the fifth session of the Board.
3. To consider and approve the resolution on the election of non-staff representative Supervisors of the fifth session of the Supervisory Committee:
 - 3.1 Election of Mr. Liu Yuanzhong as a non-staff representative Supervisors of the fifth session of the Supervisory Committee;
 - 3.2 Election of Ms. Yang Qing as a non-staff representative Supervisors of the fifth session of the Supervisory Committee; and
 - 3.3 Election of Mr. Tang Yuejun as a non-staff representative Supervisors of the fifth session of the Supervisory Committee.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Hou Yongtai
Chairman

Shanghai, the PRC
14 June 2022

* For identification purpose only

SUPPLEMENTAL NOTICE OF 2021 ANNUAL GENERAL MEETING

Notes:

1. The Supplemental Circular detailing the above resolutions has been despatched to the Shareholders on 14 June 2022. This supplemental notice should be read in conjunction with the First Notice, the First Circular and the Supplemental Circular.
2. Save for the inclusion of new resolutions as set out in this supplemental notice, there are no other changes to the resolutions set out in the First Notice. Please refer to the First Notice and the First Circular for details of other resolutions to be proposed at the AGM, closure of register of members, eligibility for attending and voting at the AGM, registration procedures for attending the AGM, the voting method and other relevant matters.
3. This supplemental notice is enclosed with a revised form of proxy of AGM (the “**Revised Form of Proxy**”) which sets out the abovementioned resolutions.

IMPORTANT NOTICE: The Revised Form of Proxy shall supersede the form of proxy which was enclosed with the notice and the circular of the Company dated 20 May 2022 in relation to the AGM (the “**Original Form of Proxy**”) and has been despatched to the Shareholders. Shareholders who have duly completed and returned the Original Form of Proxy shall note that the Original Form of Proxy is no longer applicable to the AGM.

To be valid, H Shareholders who intend to appoint a proxy to attend the AGM and vote on the resolutions set out in the First Notice and this supplemental notice are requested to complete the Revised Form of Proxy in accordance with the instructions printed thereon, the Revised Form of Proxy and notarised power of attorney or other document of authorisation (if any) must be delivered to the Company’s H Share registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not less than 24 hours before the time appointed for the AGM or any adjournment thereof (as the case may be), i.e. not later than 1:00 p.m. on Tuesday, 28 June 2022. Completion and return of the Revised Form of Proxy will not preclude Shareholders from attending and vote at the AGM should they wish to do so.